名称 | H3B-5942 |
描述 | H3B-5942 belongs to a class of ERα antagonists referred to as selective estrogen receptor covalent antagonists (SERCA). |
激酶实验 | ERαWT (297–554) and mutant (297–554) proteins were incubated in 50 mmol/L Tris pH 8.0, 150 mmol/L NaCl, 5% glycerol, and 1 mmol/L TCEP with a 2-fold excess of compound (2 μmol/L H3B-5942:1 μmol/L ERα protein solution) at 4°C overnight.?Mass analyses were carried out (ESI source, 4.0 kV ionization voltage, 250°C capillary temperature, 10 arb sheath gas, S-lens RF level 65) coupled with an Accela Open AS 1250.?Samples (10 μL) were desalted on a C4 column ( 2.1 × 150 mm, 2.6 μm) with a gradient from 5% to 95% B over 10 minutes.?Eluent A consisted of 0.1% formic acid in water, and eluent B consisted of 0.1% formic acid in acetonitrile.?The flow was set to 400 nL/minute.?All solvents were LC/MS grade .?The mass spectrometer was run in positive mode collecting full scan at R = 70,000 from m/z 500 to m/z 2,000.?Data were collected with the Xcalibur 3.1 software. |
动物实验 | Animals were selected based on TV and randomized into treatment groups of 6 to 8 animals per group.?Single-agent or combination treatments were started on day 0 and continued for the duration of the study.?H3B-5942 was administered orally, tamoxifen was given Q2D, fulvestrant was given?, and palbociclib was administered orally ?Each treatment was administered based on BW (10 mL/kg).?H3B-5942 was formulated daily in 10% 2-Hydroxypropyl-β-CycloDextrin (HPβCD) in 5% dextrose, tamoxifen was formulated in 95% peanut oil/5% ethanol (EtOH), clinical-grade fulvestrant was administered, and palbociclib was formulated in 25 mmol/L sodium bicarbonate, 15 mmol/L lactic acid solution with 2% Cremophor EL.?The BW measurements were performed daily, and tumor measurements were recorded twice a week. |
体外活性 | H3B-5942以30至300 mg/kg的剂量每日一次口服(q.d.×1),在血浆和肿瘤中的暴露量呈剂量成比例的增加,同时ERαY537S/WT ST941肿瘤模型中的ERα靶基因PGR和NPY1R的表达呈剂量成比例的降低。H3B-5942以200 mg/kg的剂量进行单次或重复给药,可以抑制大量直接的ERα靶基因,其中q.d.×1给药能够在给药后最长维持72小时的靶基因抑制效果,且q.d.×3(连续3天每日一次给药)展现出对PGR和NPY1R的最强抑制。 |
体内活性 | 单次或重复给予H3B-5942(每次200 mg/kg)能够抑制一大组直接ERα靶基因,其中q.d.×1(每天一次)给药可维持靶基因抑制至多达72小时,而q.d.×3(每天三次)给药在PGR和NPY1R上展现出最强的抑制效果。 |
存储条件 | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 50 mg/mL (101.08 mM)
|
关键字 | Inhibitor | H3B5942 | Estrogen Receptor/ERR | H3B 5942 | H-3B-5942 | H3B-5942 | inhibit |
相关产品 | Astragaloside IV | Natamycin | Estradiol | Melatonin | Mifepristone | Estradiol benzoate | Ethisterone | Tamoxifen | Allura Red AC | Kaempferol | Cholesterol | Chrysin |
相关库 | 抑制剂库 | 经典已知活性库 | 抗癌活性化合物库 | 抗癌化合物库 | 已知活性化合物库 | 高选择性抑制剂库 | 内分泌激素分子库 | 抗COVID-19化合物库 | 抗卵巢癌化合物库 | 共价抑制剂库 |